Previous 10 | Next 10 |
2023-11-22 12:41:46 ET More on Mid-day movers stock. BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly B...
2023-11-22 08:26:36 ET More on Entrada Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics For further details see: Entrada says FDA declined to lift ...
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold on ...
2023-11-07 08:37:21 ET More on Entrada Therapeutics Seeking Alpha’s Quant Rating on Entrada Therapeutics Historical earnings data for Entrada Therapeutics Financial information for Entrada Therapeutics For further details see: Entrada Therapeutics ...
– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s Duchenne franchise with the selection of...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Entrada Therapeutics Inc. (TRDA) is expected to report $-0.55 for Q3 2023
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmac...
- In its inaugural year, DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to combat disparity and support people living with Duchenne - - Announced in conjunction with World Duchenne Awareness Day, awards are designed to uplift programs that ...
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company...
News, Short Squeeze, Breakout and More Instantly...
Entrada Therapeutics Inc. Company Name:
TRDA Stock Symbol:
NASDAQ Market:
Entrada Therapeutics Inc. Website:
2024-06-25 08:00:07 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $18.00 for TRDA on 2024-06-25 06:24:00. The adjusted price target was set to $18.00. At the time of the announcement, TRDA was trading at $14.24. TRDA currently trades -33.80% versus ...
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today an...
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments – – ENTR-601-44 demonstrat...